Background: Assessing effectiveness of the next generation probiotic Ferzym in conjunction with other probiotics for correction of the microbiocenotic status in different digestive disorders. Material and methods: 120 children aged between 6 months and 17 years, with the mean age of 9.3 ± 0.61 years, were included in the study, being admitted to Gastroenterology Department of Institute of Mother and Child. The research methods included: thorough anamnesis of the disease and comprehensive clinical examination. The clinical testing procedure included a clinical monitoring during the 10-day inpatient treatment and 1 month after the outpatient treatment. Results: A more favorable clinical and progressive improvement curve was observed in children who received Ferzym. Both the stool consistency and frequency improved faster. It has been recorded a gradual and continuous remission of the abdominal pain and decrease of the discomfort up to the 10th day of treatment. The final segment of the “treatment with probiotics” curve confirms the assumption that treatment effectiveness is maintained for about 10 days, so that it can cover the acute period of disturbances. Conclusions: Ferzym is practically the only solution in the intestinal microbiocenosis control in children with intestinal malabsorption and Coeliac disease, as the capsule does not contain dismulate gluten. Efficacy of Ferzym indicated to children with digestive disorders is a priority over the biological non-sorbit preparations and monocompetent ones because Ferzym regulates the microbiocenotic status of the small intestine and colon.